Pulmonary Squamous Cell Carcinoma Harboring EGFR Exon 19 Mutation Responded Dramatically to EGFR-TKI-A Case Report

具表皮細胞生長因子接受器突變之肺麟狀細胞癌病患使用上皮細胞生長因子接收器－酪胺酸酶抑制劑呈顯著治療效果：病例報告

李凱靈(Kai-Ling Lee) ； 林賜恩(Sey-En Lin) ； 鍾政錦(Cheng-Ching Chung) ； 蕭世欣(Shih-Hsin Hsiao) ； 鍾啟禮(Chi-Li Chung)

《胸腔醫學》 30卷3期 (2015/06) Pp. 157-163

摘要

表皮細胞生長因子接受器（Epidermal growth factor receptor，簡稱EGFR）的基因突變常見於非小細胞肺癌病患，尤其是從不抽菸、女性和肺腺癌患者。擁有此突變之病患有較好的EGFR酪胺酸酶抑制劑（Tyrosine kinase inhibitor，簡稱TKI）治療效果和預後。我們提出的個案為一個不抽菸女性患有肺麟狀細胞癌併發腦部遠處轉移，卻罕見地擁有EGFR exon 19突變，並對EGFR TKI治療有顯著的療效。此篇病例報告指出EGFR基因突變分析應可實行於肺麟狀細胞癌的病患，尤其是具有亞裔、女性和從不抽菸的特徵者，而且可為此類病人提供使用標靶治療的機會。

關鍵字

表皮細胞生長因子接受器突變 ； 上皮細胞生長因素接收器－酪胺酸酶抑制劑 ； 肺麟狀細胞癌

並列摘要

Epidermal growth factor receptor (EGFR) gene mutations are common in non-small cell lung cancer (NSCLC) patients characterized by female gender, a history of never smoking and an adenocarcinoma histology. These mutations usually predict favorable EGFR-tyrosine kinase inhibitors (TKIs) treatment efficacy and outcome. We report a non-smoking female with synchronous brain metastasis from pulmonary squamous cell carcinoma (SCC), which uncommonly harbored an EGFR exon 19 mutation and dramatically responded to EGFR TKI treatment. This case highlights that EGFR mutational analysis may be performed for pulmonary SCC patients that are East Asian females without a smoking history. The identification of EGFR mutations in pulmonary SCC may provide a treatment option using EGFR-TKIs.

並列關鍵字

epidermal growth factor receptor (EGFR) mutation ； EGFR tyrosine kinase inhibitor (TKI) ； pulmonary squamous cell carcinoma